Meta-analysis of 50 studies (9902 IBD patients on JAK inhibitors): pooled acne incidence was 8.6%, higher with upadacitinib (12.2%) than tofacitinib (2.6%) or filgotinib (2.3%), and in children (12.2% vs 7.4% adults); in RCTs, acne odds vs placebo OR 2.43.
Meta-analysisn = 9,902
Quraishi et al. Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis